Buy Stocks Easy | About Us

March 29, 2020

JNCE

Buy Jounce Therapeutics, Inc. Stock (symbol: JNCE) Easy Online

Company Name: Jounce Therapeutics, Inc.

Symbol: JNCE

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

IPO: 2017

JNCE Current Share Price

Today's JNCE ( Jounce Therapeutics, Inc. ) opening price: $8.5500

Yesterday's JNCE ( Jounce Therapeutics, Inc. ) closing price: $8.3000

Jounce Therapeutics, Inc. Stock ( symbol: JNCE ) Price Chart since IPO (2017):

12 Months Jounce Therapeutics, Inc. Stock ( symbol: JNCE ) Price Chart

Popular Questions about Jounce Therapeutics, Inc. Public Stock ( JNCE )

A: Jounce Therapeutics, Inc. stock symbol (also called stock or share ticker) is JNCE

A: Jounce Therapeutics, Inc. IPO (Initial Public Offering) took place on 2017

A: Jounce Therapeutics, Inc.'s stock (JNCE symbol) price at ther IPO (initial Public Offering) was $8.5500

Q: Is JNCE stock worth buying at the moment?

A: If you were looking for a long-term investment portfolio and had bought the 'Jounce Therapeutics, Inc. stock (symbol: JNCE) at the beginning of 2019, at the opening share price of $4.1900, with a minimum of $200, by now your shares would be worth $9746 and your profit would be $9546 - SHOW ONLY IF PROFIT.

Buy Jounce Therapeutics, Inc. Stock Easy Online

Jounce Therapeutics, Inc. Stock Ticker Price Chart since IPO:

Jounce Therapeutics, Inc. Stock Price Yesterday

Jounce Therapeutics, Inc. Stock Price – Last Week

Jounce Therapeutics, Inc. Stock Price – Last Month

Jounce Therapeutics, Inc. Stock Value Chart – 12 Months

Rate this post

Latest Stock News:

http://www.zacks.com/stock/news/655937/is-the-options-market-predicting-a-spike-in-jounce-therapeutics-jnce-stock

Is the Options Market Predicting a Spike in Jounce Therapeutics (JNCE) Stock?

Investors need to pay close attention to Jounce Therapeutics (JNCE)...

http://www.zacks.com/stock/news/655594/small-business-optimism-rises-amid-trade-jitters-5-top-picks

Small Business Optimism Rises Amid Trade Jitters: 5 Top Picks

A section of the U.S. business community - the small business segme...

http://www.zacks.com/stock/news/652378/jounce-therapeutics-inc-jnce-shares-march-higher-can-it-continue

Jounce Therapeutics, Inc. (JNCE) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor J...

http://www.zacks.com/commentary/650809/top-ranked-momentum-stocks-to-buy-for-december-2nd

Top Ranked Momentum Stocks to Buy for December 2nd

Top Ranked Momentum Stocks to Buy for December 2nd

http://www.zacks.com/stock/news/631305/healthcare-sector-outperforming-5-best-etfs-stocks-qtd

Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD

Healthcare bounced back with an outperformance starting the fourth ...

https://seekingalpha.com/article/4304686-jounce-therapeutics-inc-jnce-ceo-rich-murray-q3-2019-results-earnings-call-transcript

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q3 2019 Results - Earnings Call Transcript

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q3 2019 Results...

http://www.zacks.com/stock/news/608062/jounce-therapeutics-inc-jnce-q3-earnings-and-revenues-surpass-estimates

Jounce Therapeutics, Inc. (JNCE) Q3 Earnings and Revenues Surpass Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue sur...

http://www.globenewswire.com/news-release/2019/10/31/1938668/0/en/Jounce-Therapeutics-to-Announce-Third-Quarter-2019-Financial-Results-and-Host-Conference-Call-on-Thursday-November-7-2019.html

Jounce Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Thursday, November 7, 2019

CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Jounce Therap...

http://www.globenewswire.com/news-release/2019/10/01/1923752/0/en/Jounce-Therapeutics-to-Present-Two-Posters-from-the-JTX-4014-and-Vopratelimab-Programs-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-34th-Annual-Meeting.html

Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therap...

http://www.globenewswire.com/news-release/2019/09/17/1916610/0/en/Jounce-Therapeutics-Names-Jacquelyn-Fahey-Sandell-as-Chief-Legal-Officer-and-Corporate-Secretary.html

Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary

CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Jounce Thera...

All right reserved Buy Stocks Easy , 2019.